<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND AND PURPOSE: <z:chebi fb="1" ids="15361">Pyruvate</z:chebi> is known to be cytoprotective through <z:chebi fb="11" ids="22586">antioxidant</z:chebi> and anti-inflammatory mechanisms </plain></SENT>
<SENT sid="1" pm="."><plain>We tested the hypothesis that <z:chebi fb="1" ids="15361">pyruvate</z:chebi> protects the brain against <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>-reperfusion injury by inducing endogenous erythropoietin (EPO) expression </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: <z:chebi fb="1" ids="15361">Pyruvate</z:chebi>'s protective effect was evaluated in C6 <z:hpo ids='HP_0009733'>glioma</z:hpo> cells and HT22 neuronal cells subjected to transient oxygen <z:chebi fb="105" ids="17234">glucose</z:chebi> deprivation </plain></SENT>
<SENT sid="3" pm="."><plain>Cell viability (<z:chebi fb="0" ids="51903">calcein</z:chebi> AM assay) and expression of <z:mp ids='MP_0005039'>hypoxia</z:mp>-inducible factor-1α, EPO, Akt and Erk (immunoblot), and EPO receptor (reverse transcription-polymerase chain reaction) were analyzed </plain></SENT>
<SENT sid="4" pm="."><plain>Transient focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> in rats was induced by 2 hours middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> followed by 24 hours reperfusion </plain></SENT>
<SENT sid="5" pm="."><plain><z:chebi fb="1" ids="15361">Pyruvate</z:chebi> or saline was infused from 60 minutes occlusion until 30 minutes reperfusion </plain></SENT>
<SENT sid="6" pm="."><plain>Lesion volume and DNA fragmentation were assessed by 2,3,5-triphenyltetrazolium staining and terminal deoxynucleotidyl transferase-mediated <z:chebi fb="0" ids="17625">dUTP</z:chebi> nick end-labeling assay, respectively </plain></SENT>
<SENT sid="7" pm="."><plain>Immunoblots were conducted to determine cerebral EPO contents </plain></SENT>
<SENT sid="8" pm="."><plain>RESULTS: <z:chebi fb="1" ids="15361">Pyruvate</z:chebi> increased cell viability, <z:mp ids='MP_0005039'>hypoxia</z:mp>-inducible factor-1α, EPO, and Akt phosphorylation </plain></SENT>
<SENT sid="9" pm="."><plain>Small interfering <z:chebi fb="40" ids="33697">RNA</z:chebi> suppression of <z:mp ids='MP_0005039'>hypoxia</z:mp>-inducible factor-1α and EPO abolished <z:chebi fb="1" ids="15361">pyruvate</z:chebi>-induced cytoprotection </plain></SENT>
<SENT sid="10" pm="."><plain>In the rat <z:hpo ids='HP_0001297'>stroke</z:hpo> model, <z:chebi fb="1" ids="15361">pyruvate</z:chebi> reduced lesion volume by 84% and DNA fragmentation by 77% versus controls; increased EPO content paralleled these cerebroprotective actions of <z:chebi fb="1" ids="15361">pyruvate</z:chebi> </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSIONS: <z:chebi fb="1" ids="15361">Pyruvate</z:chebi> activation of the <z:mp ids='MP_0005039'>hypoxia</z:mp>-inducible factor-1α-EPO signaling cascade in neurons and glia could protect the brain from <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>-reperfusion injury </plain></SENT>
</text></document>